News

No Need for Nausea Treatment for Most Patients on Kynmobi

The majority of Parkinson’s patients given Sunovion‘s Kynmobi (apomorphine hydrochloride) for “off” episodes during Phase 3 clinical trials did not require additional treatment for vomiting or nausea, the company said. Indeed, an analysis found that nearly 90% of participants reached the optimal dose of Kynmobi in trials without…

Study: NSAIDs Seem to Have No Effect on Parkinson’s Incidence

The use of non-steroidal anti-inflammatory drugs (NSAIDs) seems to have no effect on the incidence of Parkinson’s disease, according to a large retrospective Norwegian study. Researchers focused on the NSAIDs prescribed most in Norway: diclofenac, ibuprofen, and naproxen. In the study “NSAID use is not associated with Parkinson’s…

Small Molecules, STARs Treat Cell Models of GBA1-linked Parkinson’s

Two investigational small molecules known as GT-02287 and GT-02329 lowered toxic protein levels in patient-derived cell models of Parkinson’s disease associated with a mutation in GBA1, their developer, Gain Therapeutics, announced. Gain is planning additional preclinical studies this year that could support applications to regulatory agencies allowing the compounds to…

Variety of Ways to Help Patients With Walking Not Widely Known

People with gait difficulties due to Parkinson’s disease make adjustments that aid in walking, but many are not aware of the variety of “compensation strategies” available to them, a study based on a patient survey reported. Some of these strategies may be more useful in certain situations or to a given…

Parkinson’s UK Opens Campaign to Heighten Awareness, Empathy

Building upon previous efforts, Parkinson’s UK has opened a monthlong marketing campaign aiming for a better understanding of Parkinson’s disease — particularly among young adults — and of the daily challenges facing patients, caregivers, and family members. Specifically, the group wants to help people more deeply understand and care…

3D Brain Organoids Capture Hallmarks ‘Only Seen in Patients’

Researchers developed “mini-brains” — midbrain-like organoids — that recapitulate for a first time two key Parkinson’s hallmarks in that organ: the formation of toxic protein clumps known as Lewy bodies and the loss of dopamine-producing neurons. A combination of two known Parkinson’s risk factors — a deficiency of the beta-glucocerebrosidase…